Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Milestone Pharmaceuticals Inc. (MIST : NSDQ)
 
 • Company Description   
Milestone Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing and commercializing the investigational new drug etripamil for the treatment of cardiovascular indications. The company's lead product candidate consists of MSP-2017, a nasal spray. Milestone Pharmaceuticals Inc. is based in Montr?al, Canada.

Number of Employees: 29

 
 • Price / Volume Information   
Yesterday's Closing Price: $5.57 Daily Weekly Monthly
20 Day Moving Average: 65,078 shares
Shares Outstanding: 29.92 (millions)
Market Capitalization: $166.68 (millions)
Beta: 3.11
52 Week High: $8.24
52 Week Low: $3.98
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -22.10% -12.27%
12 Week 3.72% 14.02%
Year To Date -14.96% 0.36%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
1111 DR. FREDERIK-PHILIPS BOULEVARD SUITE 420
-
MONTREAL,A8 H4M 2X6
CAN
ph: 514-336-0444
fax: -
ir@milestonepharma.com http://www.milestonepharma.com
 
 • General Corporate Information   
Officers
Joseph Oliveto - Chief Executive Officer
Robert Wills - Chairman of the Board
Amit Hasija - Chief Financial Officer
Michael Tomsicek - Director
Paul Truex - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 59935V107
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/10/22
Share - Related Items
Shares Outstanding: 29.92
Most Recent Split Date: (:1)
Beta: 3.11
Market Capitalization: $166.68 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.38 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.49 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/10/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.65
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -10.00%
vs. Previous Quarter: 17.50%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -36.93
12/31/21 - -33.51
09/30/21 - -25.56
ROA
03/31/22 - -35.13
12/31/21 - -31.89
09/30/21 - -24.40
Current Ratio
03/31/22 - 22.77
12/31/21 - 17.55
09/30/21 - 22.70
Quick Ratio
03/31/22 - 22.77
12/31/21 - 17.55
09/30/21 - 22.71
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -295.64
12/31/21 - -285.69
09/30/21 - -230.90
Book Value
03/31/22 - 3.37
12/31/21 - 3.77
09/30/21 - 4.27
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©